Abstract: The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient.
Type:
Grant
Filed:
November 14, 2018
Date of Patent:
October 25, 2022
Assignees:
INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER